戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lloengraftment and tolerance induction under nonmyeloablative conditioning.
2                                      Two had nonmyeloablative conditioning.
3  the donor chimerism in recipients receiving nonmyeloablative conditioning.
4 eta-T-cell receptor + T cells) and low-dose, nonmyeloablative conditioning.
5  in 21% receiving myeloablative vs. 12% with nonmyeloablative conditioning.
6 entical living-related donors after modified nonmyeloablative conditioning.
7 sed risk of failure of engraftment following nonmyeloablative conditioning.
8  = .009) and better survival (P = .04) after nonmyeloablative conditioning.
9  improve survival after allogeneic HCT after nonmyeloablative conditioning.
10 itumor responses similar to those seen after nonmyeloablative conditioning.
11 ng cells, was infused into the patient after nonmyeloablative conditioning.
12 e disappearance of gene-modified cells after nonmyeloablative conditioning.
13  163 patients undergoing allogeneic HCT with nonmyeloablative conditioning.
14 ns (RLIs) to mixed chimeras established with nonmyeloablative conditioning.
15 iagnosed with advanced CLL were treated with nonmyeloablative conditioning (2 Gy total-body irradiati
16  wk of age using MHC-matched donor cells and nonmyeloablative conditioning (550 cGy irradiation).
17                       Many patients received nonmyeloablative conditioning; a significant proportion
18                          We demonstrate that nonmyeloablative conditioning achieves mixed hematopoiet
19 nt long-term benefit when patients are given nonmyeloablative conditioning and ADA enzyme-replacement
20  administration of HAART was feasible during nonmyeloablative conditioning and after HCT.
21 nolate mofetil, was first demonstrated after nonmyeloablative conditioning and allografting using hum
22  In the present studies, we demonstrate that nonmyeloablative conditioning and BM cell infusion modul
23 ts in MHC-mismatched nonhuman primates after nonmyeloablative conditioning and donor bone marrow tran
24 nhuman primate (NHP) kidney recipients after nonmyeloablative conditioning and donor bone marrow tran
25 sm was transient, which was most common with nonmyeloablative conditioning and fully rather than hapl
26 patients with advanced CLL when treated with nonmyeloablative conditioning and hematopoietic cell tra
27    Four of five dogs with CLAD that received nonmyeloablative conditioning and infusion of autologous
28 equency and severity of hepatic injury after nonmyeloablative conditioning and its relationship to ou
29         This promotes engraftment even after nonmyeloablative conditioning and limits graft-versus-ho
30                      Eight monkeys underwent nonmyeloablative conditioning and major histocompatibili
31 Baboon BMT to treat AIDS was attempted using nonmyeloablative conditioning and resulted in transient
32 ells can be induced after fludarabine-based, nonmyeloablative conditioning and that it serves as a pl
33  in a subgroup of patients who had undergone nonmyeloablative conditioning and transplantation.
34 established lupus-like disease that received nonmyeloablative conditioning and transplants of (MHC) h
35 ression analysis: use of 2 UCB units, use of nonmyeloablative conditioning, and absence of antithymoc
36            In the present studies, we used a nonmyeloablative conditioning approach to establish chim
37 hese findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extendin
38 s had enhanced short-term engraftment, after nonmyeloablative conditioning, as compared to controls.
39             Thus, tailoring the intensity of nonmyeloablative conditioning based on prior chemotherap
40                             Tolerance with a nonmyeloablative conditioning can allow successful pancr
41 ties of overall survival of 41% and 29% with nonmyeloablative conditioning compared with 45% and 24%
42 all survival at 2 years of 70% and 57% after nonmyeloablative conditioning compared with 78% and 50%
43 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning consisting of 2 Gy total b
44    In a canine model of allogeneic HCT after nonmyeloablative conditioning, DST to skin grafts was ev
45   Mixed chimeras prepared with low-intensity nonmyeloablative conditioning exhibit systemic tolerance
46                Seventy-one patients received nonmyeloablative conditioning, fludarabine (30 mg/m(2)/d
47                                              Nonmyeloablative conditioning followed by a T-cell-deple
48 shed in mismatched kidney recipients through nonmyeloablative conditioning followed by infusion of a
49 ated patients who had ADA-SCID with busulfan nonmyeloablative conditioning followed by transplantatio
50 this area will help to establish the role of nonmyeloablative conditioning for allografting.
51 e mechanism for total body irradiation-based nonmyeloablative conditioning for BM transplantation, an
52 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignanci
53 versus-host disease (GVHD) prophylaxis after nonmyeloablative conditioning for HLA class I or II mism
54 gs have uncomplicated parturitions following nonmyeloablative conditioning for SCT.
55                                              Nonmyeloablative conditioning (group 1) in the absence o
56 crease of IgM and IgG) in baboons undergoing nonmyeloablative conditioning (group 2).
57 -intensity conditioning without melphalan or nonmyeloablative conditioning had increased risk of rela
58                                              Nonmyeloablative conditioning has significantly reduced
59 plantation of purified allogeneic HSCs after nonmyeloablative conditioning has the potential to rever
60 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had adv
61  bone marrow and kidney transplant following nonmyeloablative conditioning in a patient with multiple
62  and consider reduced intensity conditioning/nonmyeloablative conditioning in patients who have achie
63 matopoietic cell transplantation (HCT) after nonmyeloablative conditioning in patients with hematolog
64 outcomes were seen with allogeneic HCT after nonmyeloablative conditioning in selected patients who h
65 blative conditioning but is persistent after nonmyeloablative conditioning, in which recipient hemato
66               Mixed chimerism established by nonmyeloablative conditioning induces long-term acceptan
67                         Allogeneic HCT after nonmyeloablative conditioning is a promising salvage str
68                  Although the major role for nonmyeloablative conditioning is to control alloreactive
69 Invasive mold infections occurred late after nonmyeloablative conditioning (median, day 107), with pr
70 oablative regimens suggested that the use of nonmyeloablative conditioning might be associated with l
71 ematopoietic stem cell transplantation after nonmyeloablative conditioning might become the procedure
72 s-leukemia effects, and allogeneic HCT after nonmyeloablative conditioning might prolong median survi
73       The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored furth
74 = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens.
75 ortality among 60 consecutive patients given nonmyeloablative conditioning (nonablative patients) to
76 ed in laboratory animals and in humans after nonmyeloablative conditioning of the host and infusion o
77 ity was estimated at 22% (36 patients) after nonmyeloablative conditioning, of which 39% (14 patients
78                                        Using nonmyeloablative conditioning, our laboratory has develo
79              Treatment recipients received a nonmyeloablative conditioning protocol with rabbit-antit
80 s has prompted the development of less toxic nonmyeloablative conditioning protocols, the goal of whi
81 CI, 1.39-13.81]), and in the late phase were nonmyeloablative conditioning regimen (HR, 35.08 [95% CI
82   In another study, baboons (n=9) received a nonmyeloablative conditioning regimen (NMCR) aimed at in
83 rsus-host disease (GVHD) in mice receiving a nonmyeloablative conditioning regimen allowing establish
84 ve T cells in mixed chimeras prepared with a nonmyeloablative conditioning regimen and allogeneic bon
85 arrow transplantation using a short-duration nonmyeloablative conditioning regimen and posttransplant
86               We have previously described a nonmyeloablative conditioning regimen based on recipient
87                                          The nonmyeloablative conditioning regimen comprising total l
88                                    We used a nonmyeloablative conditioning regimen consisting of cycl
89 issue of Blood, Muller et al showed, using a nonmyeloablative conditioning regimen consisting of tota
90                               We have used a nonmyeloablative conditioning regimen consisting of tota
91                       Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed
92 oclonal antibody (mAb) (211)At-CD45-B10 as a nonmyeloablative conditioning regimen for dog-leukocyte-
93 afts undergoing this complete short-duration nonmyeloablative conditioning regimen had durable lung a
94                                            A nonmyeloablative conditioning regimen has recently been
95 ound for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction wit
96 Mixed hematopoietic chimerism induced with a nonmyeloablative conditioning regimen leads to donor-spe
97                      Using a GVHD protective nonmyeloablative conditioning regimen of total lymphoid
98 n anti-alphaGal antibody production; (iii) a nonmyeloablative conditioning regimen reduces the rate o
99 ppa light-chain multiple myelomas received a nonmyeloablative conditioning regimen that consisted of
100                       We took advantage of a nonmyeloablative conditioning regimen that permits allog
101 oxp3+ regulatory T cells (Tregs) surviving a nonmyeloablative conditioning regimen that undergo robus
102 design of clinical trials using (213)Bi as a nonmyeloablative conditioning regimen with minimal toxic
103                           Group 1 received a nonmyeloablative conditioning regimen without porcine BM
104                Twenty-one animals received a nonmyeloablative conditioning regimen.
105 elf-derived differentiation antigens after a nonmyeloablative conditioning regimen.
106  combination by using a relatively nontoxic, nonmyeloablative conditioning regimen.
107 irradiation (TBI) were compared as part of a nonmyeloablative conditioning regimen.
108 o investigate the effect of a pharmacologic, nonmyeloablative, conditioning regimen on the developmen
109         Recent clinical reports suggest that nonmyeloablative conditioning regimens afford better out
110                                              Nonmyeloablative conditioning regimens are increasingly
111  This has prompted the recent development of nonmyeloablative conditioning regimens for allogeneic he
112 ype may therefore have an adjunctive role in nonmyeloablative conditioning regimens for allogeneic st
113 s (SMNs) in the era of reduced-intensity and nonmyeloablative conditioning regimens for hematopoietic
114 ens, and they provide support for the use of nonmyeloablative conditioning regimens in preclinical pr
115 re, our studies suggest the possibility that nonmyeloablative conditioning regimens might be effectiv
116                         Transplantation with nonmyeloablative conditioning regimens relying on the gr
117                                   Less toxic nonmyeloablative conditioning regimens that have the pot
118 inition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonl
119  treatment-related mortality associated with nonmyeloablative conditioning regimens, the question of
120 oviral-mediated gene therapy in CLAD using 2 nonmyeloablative conditioning regimens--200 cGy total bo
121 ols in cases of limited graft cell number or nonmyeloablative conditioning regimens.
122 ulticenter clinical trials are incorporating nonmyeloablative conditioning, related haploidentical do
123                        In summary, following nonmyeloablative conditioning, simultaneous administrati
124 PS was significantly lower at 120 days after nonmyeloablative conditioning than conventional conditio
125  unrelated donors who successfully underwent nonmyeloablative conditioning therapy followed by infusi
126                                              Nonmyeloablative conditioning using total lymphoid irrad
127       In murine mixed chimeras prepared with nonmyeloablative conditioning, we previously showed that
128 ing the first year after allogeneic HCT with nonmyeloablative conditioning were 19%, 15%, 14%, and 5%
129 c stem cell (HSC) engraftment following this nonmyeloablative conditioning were evaluated.
130                               Patients given nonmyeloablative conditioning were older than those give
131                           Patients receiving nonmyeloablative conditioning were older, more frequentl
132 t factor predicting lessened RRT and NRM was nonmyeloablative conditioning, whereas high pretransplan
133 jections occurred after reduced-intensity or nonmyeloablative conditioning, which associated with poo
134         Conclusion: The results suggest that nonmyeloablative conditioning with (211)At-CD45-B10 coul
135                     The results suggest that nonmyeloablative conditioning with (213)Bi-labeled anti-
136                                              Nonmyeloablative conditioning with 200 cGy TBI and anti-
137 nt study, we tested BDDpfVIII activity after nonmyeloablative conditioning with busulfan, cyclophosph
138 opoietic chimerism can be achieved following nonmyeloablative conditioning with cyclophosphamide, T c
139 ed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy
140 -incompatible cells can engraft stably after nonmyeloablative conditioning with immunosuppressive che
141                             Group 2 received nonmyeloablative conditioning with pig BM transplantatio
142                                              Nonmyeloablative conditioning with posttransplantation h
143 hematopoietic stem cell transplantation, and nonmyeloablative conditioning with total lymphoid irradi
144 ific tolerance can be achieved with mPBMC in nonmyeloablative conditioning without GVHD.

 
Page Top